Press Releases & News ArticlesNovember, 2022The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of AgingRead More »November, 2022Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related DiseasesRead More »October, 2022BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.Read More »February, 2022Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1Read More »November, 2021CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)Read More »February, 2020Juvena Therapeutics Interviewed– Embryonic Proteins for Tissue Regeneration- Jan 2020Read More »January, 2020Juvena Therapeutics Listed as 1 of 3 Ground Breaking Longevity StartupsRead More »October, 2019CEO Hanadie Yousef’s Entrepreneurship Recognized by Spark at StanfordRead More »May, 2019CEO Hanadie Yousef’s Most Recent Publication in Nature MedicineRead More »March, 2019Medium Blog Parameter Mentions Juvena TherapeuticsRead More »March, 2019Juvena Therapeutics Mentioned in ForbesRead More »July, 2018Juvena Therapeutics Mentioned in Middle Market GrowthRead More »January, 2017Antibody Can Protect Brains From the Ageing Effects of Old BloodRead More »July, 2016Hanadie Yousef, Cofounder and CEO, in Scope by Stanford MedicineRead More »May, 2016The Bloody Battle Against AgingRead More »June, 2015Featured in Vice: Engineering the End of AgingRead More »May, 2015CEO Highlighted in the Daily CalifornianRead More »
